View Document Preview and Link Document Date: 2014-06-03 10:39:51 Open Document File Size: 300,40 KB Share Result on Facebook
City Madrid / Barcelona / LEXINGTON / / Company Synageva BioPharma Corp. / / Country Spain / / / Event FDA Phase / / Facility Lipid Clinic / Hospital Clínic / / IndustryTerm satellite symposium / biopharmaceutical company developing therapeutic products / company-sponsored satellite symposium / / MedicalCondition Always Familial Hypercholesterolemia / mucopolysaccharidoses / accelerated atherosclerosis / LAL Deficiency LAL Deficiency / rare diseases / disease / rare autosomal recessive lysosomal storage disease / dyslipidemia / cirrhosis / Lysosomal Acid Lipase Deficiency / cholecystitis/cholelithiasis / Cholesteryl Ester Storage Disease / Wolman disease / diseases / diarrhea / deficiency / LAL Deficiency / B syndrome / / MedicalTreatment enzyme replacement therapy / / Organization CONGRESS / Institut d’Investigacions Biomèdiques August Pi Sunyer / European Medicines Agency / Ros / M.D. / Lipid Clinic / Endocrinology & Nutrition Service / U.S. Food and Drug Administration / Ministry of Health / / Person Radhika Tripuraneni / MPS IIIB / Emilio Ros / Matthew Osborne / / / Position Medical Director / animal model / / Product SBC-103 / / ProvinceOrState Massachusetts / / Technology alpha / antibodies / / URL www.synageva.com / / SocialTag 
SYNAGEVA BIOPHARMA™ HIGHLIGHTS DATA PRESENTATIONS AND SATELLITE SYMPOSIUM AT THE EUROPEAN ATHEROSCLEROSIS SOCIETY CONGRESS LEXINGTON, Mass., June 3, [removed]Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharm